spironolactone has been researched along with cardiovascular agents in 42 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.76) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (45.24) | 29.6817 |
| 2010's | 17 (40.48) | 24.3611 |
| 2020's | 4 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, PW; Borer, J; Fleming, T; Lipicky, R | 1 |
| McKelvie, R | 2 |
| Rittenhouse, SK | 1 |
| Aguilar, JC; Cleland, J; Cohen-Solal, A; Dietz, R; Eastaugh, J; Follath, F; Freemantle, N; Gavazzi, A; Hobbs, R; Komajda, M; Korewicki, J; Madeira, HC; Mason, J; Moiseyev, VS; Preda, I; Swedberg, K; Van Gilst, WH; Widimsky, J | 1 |
| Baez, J; Byng, G; Laakso, JA; Mocek, UM; Preisig, CL; Wang, PT | 1 |
| Pitt, B; Rajagopalan, S | 1 |
| FARDEAU, M | 1 |
| BRIGGS, AH; GRENFELL, RF; HOLLAND, WC | 1 |
| Gaulden, L | 1 |
| Cowley, AJ; McKenzie, DB | 1 |
| Riggs, JM | 1 |
| Barnes, BJ; Howard, PA | 1 |
| Laustsen, G; Wimmett, L | 1 |
| Bułło, B; Konopa, J; Rutkowski, B | 1 |
| Böhm, M; Eckel, L; Grube, M; Haney, J; Jedlitschky, G; Kroemer, HK; Meissner, K; Meyer zu Schwabedissen, HE; Möritz, KU; Präger, D; Rosskopf, D | 1 |
| George, J; Struthers, AD | 1 |
| Blankesteijn, WM; Daemen, MJ; Fujimoto, A; Fujimoto, S; Hofstra, L; Isobe, S; Li, P; Lovhaug, D; Narula, J; Narula, N; Petrov, A; Pitt, B; Reutelingsperger, C; Smits, JF; van den Borne, SW; Vannan, MA; Wong, ND; Zandbergen, HR; Zannad, F | 1 |
| Miller, AB; Shafiq, MM | 1 |
| Akchurin, RS; Chernova, NA; Erastova, NV; Grishin, IR; Karpov, IuA; Latypov, RS; Lopukhova, VV; Mareev, IuV; Saidova, MA; Sapel'nikov, OV | 1 |
| Choudhry, NK; Levin, R; Setoguchi, S; Shrank, WH; Winkelmayer, WC | 1 |
| Krum, H; McMurray, JJ; Pitt, B; Pocock, SJ; Shi, H; Swedberg, K; van Veldhuisen, DJ; Vincent, J; Zannad, F | 1 |
| Bajekal, M; Capewell, S; Hawkins, NM; Love, H; O'Flaherty, M; Raine, R; Scholes, S | 1 |
| Krum, H; Watanabe, M | 1 |
| Borlaug, BA | 1 |
| Andreev, DA; Gappoeva, ZK; Giliarov, MIu; Sychev, DA | 1 |
| Heritier, S; Leung, DY; Leung, M; Mihailidou, AS; Wong, VW | 1 |
| Ahmed, A; Angioi, M; Carillo, S; Fay, R; Pitt, B; Sutradhor, SC; Vincent, J; Zannad, F; Zhang, Y | 1 |
| Maggioni, AP | 1 |
| Eurich, DT; McAlister, FA; Murphy, GK | 1 |
| Sayer, GT; Tannenbaum, S | 1 |
| Jorde, UP; Lyons, JJ; Mody, KP; Uriel, N | 1 |
| Follath, F | 1 |
| Kanorskiy, SG; Pokrovskiy, VM; Tregubov, VG | 1 |
| Brugts, JJ; Brunner-La Rocca, HP; Hoes, AW; Linssen, GC; Rademaker, PC; Schaafsma, HJ; Smeele, FJ; van de Kamp, HJ; van Drimmelen, AA; Westendorp, PH | 1 |
| Feng, V; Gonzales, K; Haas, MJ; Mooradian, AD; Onstead-Haas, L | 1 |
| Ivkin, D; Karpov, A; Kaschina, E; Krasnova, M; Kulikov, A; Okovityi, S; Smirnov, A | 1 |
| Anghel, L; Bostan, M; Enachi, Ș; Marcu, D; Ovanez Balasanian, M; Pleșoianu, C; Șalaru, D; Sascău, RA; Stătescu, C; Țăpoi, L; Ureche, C | 1 |
| Koiwa, H; Matsushima, S; Morisaki, H; Morisaki, T; Naya, M; Tsujinaga, S; Yokota, T | 1 |
14 review(s) available for spironolactone and cardiovascular agents
| Article | Year |
|---|---|
Heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Combined Modality Therapy; Defibrillators, Implantable; Digoxin; Exercise; Heart Failure; Humans; Patient Care Team; Randomized Controlled Trials as Topic; Spironolactone; Survival Rate; Treatment Outcome | 2002 |
Spironolactone for heart failure: a worthy addition to therapy.
Topics: Cardiovascular Agents; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2001 |
Heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Combined Modality Therapy; Defibrillators, Implantable; Digoxin; Exercise; Heart Failure; Humans; Spironolactone | 2002 |
Aldosterone as a target in congestive heart failure.
Topics: Aldosterone; Cardiovascular Agents; Endothelium, Vascular; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Muscle, Smooth, Vascular; Myocardium; Plasminogen Activator Inhibitor 1; Progesterone; Randomized Controlled Trials as Topic; Spironolactone; Treatment Outcome | 2003 |
Diagnosis and management of heart failure in the long-term care setting.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Chronic Disease; Digoxin; Diuretics; Drug Interactions; Echocardiography; Heart Failure; Humans; Long-Term Care; Receptors, Angiotensin; Spironolactone | 2003 |
Drug therapy in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Agents; Chronic Disease; Digoxin; Diuretics; Female; Heart Failure; Humans; Male; Middle Aged; Spironolactone; Vasodilator Agents | 2003 |
New therapies for heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Diuretics; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Hydrazones; Natriuretic Agents; Natriuretic Peptide, Brain; Neurotransmitter Agents; Pyridazines; Simendan; Spironolactone; Treatment Outcome; United States | 2004 |
Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
Topics: Animals; Cardiovascular Agents; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Molecular Structure; Randomized Controlled Trials as Topic; Spironolactone | 2005 |
2004 drug approval highlights: FDA update.
Topics: Administration, Cutaneous; Amlodipine; Anti-Bacterial Agents; Antidepressive Agents; Bronchodilator Agents; Cardiovascular Agents; Drug Approval; Drug Combinations; Duloxetine Hydrochloride; Eplerenone; Estradiol; Excitatory Amino Acid Antagonists; Female; Gastrointestinal Agents; Heptanoic Acids; Humans; Ketolides; Male; Memantine; Osteoporosis, Postmenopausal; Pyrroles; Rifamycins; Rifaximin; Scopolamine Derivatives; Spironolactone; Thiophenes; Tiotropium Bromide; United States | 2005 |
Evaluation of the aldosterone-blocking agent eplerenone in hypertension and heart failure.
Topics: Animals; Antihypertensive Agents; Cardiovascular Agents; Drug and Narcotic Control; Eplerenone; Heart Failure; Humans; Hypertension; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Treatment Outcome | 2007 |
Blocking aldosterone in heart failure.
Topics: Aldosterone; Cardiovascular Agents; Drug Therapy, Combination; Eplerenone; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Eplerenone for the treatment of cardiovascular disorders.
Topics: Aldosterone; Animals; Cardiovascular Agents; Cardiovascular Diseases; Eplerenone; Humans; Hydrocortisone; Mineralocorticoid Receptor Antagonists; Receptors, Mineralocorticoid; Spironolactone | 2012 |
Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cardiovascular Agents; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Phosphodiesterase 5 Inhibitors; Renin-Angiotensin System; Spironolactone; Stroke Volume; Water-Electrolyte Imbalance | 2015 |
Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Cardiovascular Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Repositioning; Humans; Myosins; Sodium Channel Blockers; Spironolactone; Vasodilator Agents | 2021 |
2 trial(s) available for spironolactone and cardiovascular agents
| Article | Year |
|---|---|
Eplerenone in patients with systolic heart failure and mild symptoms.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Defibrillators, Implantable; Double-Blind Method; Eplerenone; Female; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Proportional Hazards Models; Spironolactone | 2011 |
Rationale and design of a randomized trial on the impact of aldosterone antagonism on cardiac structure and function in diabetic cardiomyopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Clinical Protocols; Collagen; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Diastole; Double-Blind Method; Drug Therapy, Combination; Echocardiography, Doppler; Eplerenone; Fibrosis; Humans; Mineralocorticoid Receptor Antagonists; Myocardium; New South Wales; Prospective Studies; Recovery of Function; Research Design; Spironolactone; Systole; Time Factors; Treatment Outcome; Ventricular Function, Left | 2013 |
26 other study(ies) available for spironolactone and cardiovascular agents
| Article | Year |
|---|---|
Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001.
Topics: Adrenergic beta-Antagonists; Advisory Committees; Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Black People; Canada; Cardiovascular Agents; Drug Approval; Heart Failure; Humans; Hyperkalemia; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Renal Insufficiency; Spironolactone; Survival Rate; Tetrazoles; United States; United States Food and Drug Administration; Valine; Valsartan | 2001 |
The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel Blockers; Cardiac Glycosides; Cardiac Output, Low; Cardiovascular Agents; Europe; Female; Fibrinolytic Agents; Health Surveys; Hospitalization; Humans; Male; Multivariate Analysis; Platelet Aggregation Inhibitors; Quality of Health Care; Spironolactone | 2003 |
Biotransformations of the cardiovascular drugs mexrenone and canrenone.
Topics: Biotransformation; Canrenone; Cardiovascular Agents; Chromatography, High Pressure Liquid; Fermentation; Fungi; Magnetic Resonance Spectroscopy; Molecular Structure; Mortierella; Spironolactone; Stereoisomerism | 2003 |
[MYASTHENIA].
Topics: Ammonium Compounds; Blood; Cardiovascular Agents; Child; Diagnosis; Endocrinology; Ephedrine; Guanidines; Humans; Muscle Relaxants, Central; Myasthenia Gravis; Neostigmine; Pathology; Physostigmine; Quaternary Ammonium Compounds; Respiratory Insufficiency; Spironolactone; Thymus Gland | 1964 |
A DOUBLE-BLIND EVALUATION OF ANTIHYPERTENSIVE DRUGS.
Topics: Antihypertensive Agents; Biomedical Research; Blood Pressure; Blood Pressure Determination; Cardiovascular Agents; Double-Blind Method; Ergot Alkaloids; Guanethidine; Methysergide; Pharmacology; Placebos; Posture; Reserpine; Selective Serotonin Reuptake Inhibitors; Serotonin; Spironolactone | 1964 |
[Which patient needs an aldosterone antagonist?].
Topics: Cardiovascular Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone | 2003 |
Avoid the risks of mixed medications. How to minimize dangerous interactions with cardiovascular drugs.
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Agents; Drug Interactions; Eplerenone; Ezetimibe; Fluorobenzenes; Humans; Polypharmacy; Pyrimidines; Rosuvastatin Calcium; Spironolactone; Sulfonamides | 2003 |
[Late drug-induced hyperkalemia in a patient with congestive heart failure].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Diuretics; Female; Heart Failure; Humans; Hyperkalemia; Renal Dialysis; Spironolactone; Treatment Outcome | 2005 |
Uptake of cardiovascular drugs into the human heart: expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5).
Topics: Aged; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Agents; Cell Line; Dogs; Endothelial Cells; Female; Genotype; Humans; Male; Methylhydrazines; Middle Aged; Myocardium; Organic Cation Transport Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger; Solute Carrier Family 22 Member 5; Spironolactone; Transfection; Verapamil | 2006 |
Molecular imaging for efficacy of pharmacologic intervention in myocardial remodeling.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Carbocyanines; Cardiovascular Agents; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Fibrillar Collagens; Fibroblasts; Fibrosis; Losartan; Mice; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Oligopeptides; Predictive Value of Tests; Spironolactone; Technetium; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left; Ventricular Remodeling | 2009 |
[Application of cardiac resynchronization therapy and ivabradine in a patient with chronic heart failure].
Topics: Benzazepines; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiovascular Agents; Digoxin; Diuretics; Echocardiography; Electrocardiography; Furosemide; Heart Atria; Heart Failure; Heart Rate; Heart Ventricles; Humans; Ivabradine; Male; Middle Aged; Myocardial Infarction; Spironolactone; Treatment Outcome | 2010 |
Temporal trends in adherence to cardiovascular medications in elderly patients after hospitalization for heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Cohort Studies; Female; Heart Failure; Humans; Insurance Claim Review; Male; Medication Adherence; Patient Discharge; Socioeconomic Factors; Spironolactone; Time Factors | 2010 |
Community care in England: reducing socioeconomic inequalities in heart failure.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Community Health Services; Drug Utilization; England; Female; Health Status Indicators; Healthcare Disparities; Heart Failure; Humans; Incidence; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; National Health Programs; Poverty; Prevalence; Socioeconomic Factors; Spironolactone; Survival Rate | 2012 |
Heart failure: Aldosterone antagonism for HFpEF.
Topics: Biomarkers; Cardiovascular Agents; Heart Failure, Diastolic; Humans; Mineralocorticoid Receptor Antagonists; Spironolactone; Stroke Volume; Treatment Outcome; Ventricular Remodeling | 2013 |
[Bleeding in the appointment of dabigatran in the patients with renal insufficiency caused by coadministration of spironolactone and ACE inhibitors].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Agents; Dabigatran; Drug Interactions; Drug Therapy, Combination; Heart Failure; Hemorrhage; Humans; Male; Renal Insufficiency, Chronic; Spironolactone; Treatment Outcome; Withholding Treatment | 2013 |
Eplerenone-mediated regression of electrical activation delays and myocardial fibrosis in heart failure.
Topics: Action Potentials; Animals; Anti-Inflammatory Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cardiovascular Agents; Disease Models, Animal; Dogs; Eplerenone; Fibrosis; Heart Failure; Hypertrophy, Left Ventricular; Inflammation Mediators; Interleukin-6; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Spironolactone; Time Factors; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
Topics: Aged; Cardiovascular Agents; Cardiovascular Diseases; Cause of Death; Comorbidity; Coronary Thrombosis; Disease Progression; Electrocardiography; Eplerenone; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Spironolactone; Treatment Outcome | 2014 |
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?].
Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Ethnicity; Europe; Female; Georgia (Republic); Heart Failure; Humans; Internationality; Male; Metoprolol; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Russia; Sample Size; Spironolactone; Ticagrelor; Ticlopidine; Tolvaptan | 2014 |
Cardiovascular medication utilization and adherence among heart failure patients in rural and urban areas: a retrospective cohort study.
Topics: Adrenergic Antagonists; Aged; Aged, 80 and over; Canada; Cardiotonic Agents; Cardiovascular Agents; Digoxin; Diuretics; Female; Follow-Up Studies; Heart Failure; Humans; Male; Medication Adherence; Renin-Angiotensin System; Retrospective Studies; Rural Population; Spironolactone; Treatment Outcome; Urban Population | 2015 |
A cold taken to heart.
Topics: Adenoviridae Infections; Adult; Biopsy; Cardiovascular Agents; Combined Modality Therapy; Defibrillators; Disease Progression; Emergencies; Female; Fever; Heart-Assist Devices; Hemodynamics; Humans; Myocarditis; Myocardium; Parvoviridae Infections; Pericarditis; Shock, Cardiogenic; Spironolactone; Ventricular Dysfunction, Left | 2015 |
[Cardiovascular drugs in aged and multimorbid patients].
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Comorbidity; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Eplerenone; Female; Guideline Adherence; Heart Failure; Humans; Hypertension; Male; Mineralocorticoid Receptor Antagonists; Pacemaker, Artificial; Risk Factors; Spironolactone | 2015 |
[Regulatory Adaptive Status in Assessment of Efficacy of Pharmacotherapy and Prognostication of Complications in Functional Class III Chronic Heart Failure].
Topics: Aged; Benzazepines; Cardiovascular Agents; Chronic Disease; Echocardiography; Exercise Test; Female; Heart Failure; Humans; Hypertension; Ivabradine; Male; Metoprolol; Middle Aged; Quinapril; Random Allocation; Spironolactone; Tetrahydroisoquinolines; Treatment Outcome; Ventricular Function, Left | 2016 |
Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction: The CHECK-HF Registry.
Topics: Age Factors; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Chronic Disease; Cross-Sectional Studies; Female; Furosemide; Guideline Adherence; Heart Failure; Humans; Ivabradine; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Netherlands; Practice Guidelines as Topic; Registries; Renin-Angiotensin System; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Stroke Volume | 2019 |
High-throughput analysis identifying drugs that reduce oxidative and ER stress in human coronary artery endothelial cells.
Topics: Adrenergic beta-Antagonists; Alkaline Phosphatase; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Calcitriol; Cardiovascular Agents; Cell Survival; Cells, Cultured; Coronary Vessels; Endoplasmic Reticulum Stress; Endothelial Cells; Estradiol; High-Throughput Screening Assays; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Oxidative Stress; Spironolactone; Superoxides | 2020 |
Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats.
Topics: Animals; Benzhydryl Compounds; Bisoprolol; Cardiovascular Agents; Chronic Disease; Disease Models, Animal; Exercise Tolerance; Fosinopril; Glucosides; Heart Failure; Male; Myocardial Infarction; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Spironolactone; Ventricular Dysfunction, Left; Ventricular Function, Left | 2020 |
Loeys-Dietz Cardiomyopathy? Long-term Follow-up After Onset of Acute Decompensated Heart Failure.
Topics: Acute Disease; Bisoprolol; Cardiomegaly; Cardiomyopathies; Cardiovascular Agents; Echocardiography; Genetic Testing; Heart Failure; Humans; Loeys-Dietz Syndrome; Losartan; Male; Middle Aged; Mutation; Pulmonary Edema; Receptor, Transforming Growth Factor-beta Type I; Spironolactone; Treatment Outcome; Ventricular Dysfunction, Left | 2022 |